SparingVision
SparingVision is a biotechnology company focused on the discovery and development of genomic medicines for the treatment of blinding inherited retinal diseases. SparingVision’s lead product, SPVN06, is a proprietary, mutation-agnostic, AAV gene therapy product comprised of one neurotrophic factor and one enzyme reducing oxidative stress which, acting synergistically, aim at slowing or stopping the degeneration of photoreceptors which inevitably leads to blindness in retinitis pigmentosa (“RP”) patients. RP is one of the most common inherited retinal diseases that affects two million patients worldwide. There is currently no treatment approved to treat RP patients independently of their genetic background. Started in 2016 as a spin-off of the Paris Vision Institute, SparingVision has already raised more than $50 million with strategic, patient-centric investors.
